The resurgence of mental health drug development and why it matters

Published on April 16, 2025

After decades of stagnation, the field of mental health drug development is finally seeing some movement. A wave of innovation, bolstered by new science, shifting public attitudes, and landmark regulatory moments, is transforming how we understand and treat mental health conditions. “It’s like we’ve been playing the same song on repeat,” says Emma Wille, a […]

Continue reading on website
Other news

Scaling NK Cell manufacturing: From iPSCs to NK cells in a feeder-free, GMP-ready platform

April 16, 2025
Natural Killer (NK) cell treatments are not readily accessible to patients due to persistent manufacturing complexities, scalability issues, and challenges in delivery. Cellistic's iPSC-based allogeneic Echo™-NK Manufacturing Platform breaks down these barriers by enabling therapeutic developers to manufacture safe, consistent, and cost-efficient off-the-shelf NK cell therapies at scale.

How the Tariffs Could Impact Your Drug Development Supply Chain: Top 5 Things To Be Aware Of

April 16, 2025
Authors:Maria Malin, Senior DirectorRhonda Gates, Vice President US Supply Chain, Strategy & TransformationAt Abzena, we’re not just reacting to potential tariff changes—we’re striving to proactively reshape our supply chain strategy to thrive in a complex global market. In the current geopolitical landscape, and among recent discussions about tariffs on pharmaceutical products, our fully integrat